Tarantini F, Anelli L, Ingravallo G, et al. - Researchers analyzed chronic myeloid leukemia (CML) patients (n = 67) treated with dasatinib in order to determine the prevalence rates of cutaneous events during this therapy in this patient population. They also assessed the clinical and pathological features of these reactions. Among participants, 26 (39%) and 41 (61%) patients received dasatinib as first line treatment and as subsequent treatment, respectively. During dasatinib therapy, skin lesions were exhibited by 4 (5.9%) patients, mainly on the back, abdomen, thorax or leg regions. These lesions were not generalized. A mild perivascular small CD8+ T lymphocytes infiltrate with minimal epidermotropism characterized the lesions, this was suggested as the possible expression of a dasatinib-promoted lymphocyte expansion. The observed dermatologic manifestations were heterogeneous. This heterogeneity could also be associated with unknown factors particular to each CML patient. A possible link between skin lesions and dasatinib treatment was suggested. Not confusing these skin lesions with viral or bacterial infections but rather interpreting these as the clinical expression of lymphocytosis promoted by this TKI was recommended.